M 3814

Drug Profile

M 3814

Alternative Names: M-3814; MSC-2490484A

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Merck KGaA
  • Developer EMD Serono Research & Development Institute; Merck KGaA
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Small cell lung cancer
  • Phase I Chronic lymphocytic leukaemia; Solid tumours

Most Recent Events

  • 19 May 2017 Chemical structure information added
  • 30 Apr 2017 Phase-I/II clinical trials in Small cell lung cancer (Combination therapy) in USA (PO)
  • 19 Apr 2017 EMD Serono and Merck KGaA plan a phase Ib/II trial for Small cell lung cancer (Combination therapy) in USA (PO) (NCT03116971)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top